Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Top Executives at Adap.tv, AOL’s Biggest Acquisition, Are Leaving

Tim Armstrong paid $405 million for the ad tech company in September 2013. Its CEO left this month, following other top executives.

aliisik / Shutterstock
Peter Kafka
Peter Kafka covered media and technology, and their intersection, at Vox. Many of his stories can be found in his Kafka on Media newsletter, and he also hosts the Recode Media podcast.

Less than two years ago, AOL made the biggest acquisition of CEO Tim Armstrong’s tenure, paying $405 million for ad tech startup Adap.tv.

Now much of Adap.tv’s senior management has left. The most recent departure is co-founder Amir Ashkenazi, who was CEO of Adap.tv up until its sale to AOL in September 2013, and then became president of AOL’s “Platforms” technology group. Ashkenazi left earlier this month.

“Amir’s contributions to AOL will live on well past his departure and we wish him well,” an AOL rep said in a statement.

Adap.tv’s software helps people buy and sell video advertising via an exchange. AOL’s purchase represented a large bet in two crucial areas for Armstrong: “Programmatic” — that is, automated — ad buying, and video.

AOL hasn’t announced a replacement for Ashkenazi, but a person familiar with the company said his responsibilities will essentially be divvied up between Don Kennedy, who heads up the sales side of AOL’s advertising business, and Amit Kapur, who runs the company’s publisher business. Both men report to Bob Lord, who oversees all of AOL’s ad and tech operations.

Ashkenazi is one of several Adap.tv executives who have left in the last year, including Ashkenazi’s co-founder Teg Grenager, who had been the company’s chief product officer and left late in 2014. Former president Toby Gabriner left last spring.

As Kara Swisher has reported AOL is in the midst of a significant sales re-org. People familiar with Ashkenazi’s departure say it’s not directly connected to that restructuring. But former Adap.tv employees say some of the startup’s workers have had a hard time figuring out how to work with AOL’s existing employees and infrastructure.

Some high-profile Adap.tv employees remain with AOL, including Raleigh Harbour, the company’s chief operating officer and sales execs Dan Ackerman and Vijay Rao.

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh